Ontology highlight
ABSTRACT:
SUBMITTER: Lelovic N
PROVIDER: S-EPMC7554168 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
The Journal of antibiotics 20200529 11
Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL-3) facility for performing research associated with Mtb is another limitation for the development of TB drug discovery. In our screening of BSL-1 Mycobacterium spp. against a battery of TB drugs, M. smegmatis (ATCC607) exhibits good agreement with its drug susceptibility against the TB drugs under a low-nutrient cult ...[more]